Oric Pharmaceuticals, Inc. ORIC
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer.
Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Collectively, our founders and management team have a decades-long heritage of identifying and characterizing resistance mechanisms in oncology, having discovered, developed and commercialized groundbreaking medicines at companies such as Ignyta, Medivation, Aragon, Pharmacyclics, Deciphera and Genentech.
Our fully integrated research and development team is advancing a diverse pipeline of innovative clinical therapies designed to counter resistance mechanisms in cancer by leveraging our expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| SG&A | $33.2M | $28.8M | $25.6M | $25.1M | $22.0M | $13.4M | $5.7M | $3.3M | — |
| Total operating expenses | $143.0M | $142.9M | $110.8M | $91.8M | $78.9M | $74.2M | $28.6M | $22.4M | — |
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M | -$74.2M | -$28.6M | -$22.4M | — |
| Pre-tax income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M | -$73.7M | -$26.9M | -$21.4M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M | -$73.7M | -$26.9M | -$21.4M | — |
| EPS, basic | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 | — | — | — | — |
| EPS, diluted | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 | -3.36 | -14.15 | -12.32 | — |
| Shares, diluted (wtd. avg.) | 87.8M | 69.7M | 51.5M | 39.7M | 38.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.7M | $59.4M | $23.9M | $67.3M | $226.5M | $78.4M | $89.2M | $42.6M | $25.8M |
| Short-term investments | $235.8M | $196.6M | $184.8M | $139.4M | $11.0M | $215.2M | — | — | — |
| Total current assets | $288.5M | $262.2M | $212.6M | $210.5M | $240.5M | $296.7M | $90.0M | — | — |
| Property, plant and equipment | $2.4M | $2.9M | $2.9M | $3.3M | $2.4M | $2.0M | $2.2M | — | — |
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M | $299.0M | $94.1M | — | — |
| Accounts payable | $3.8M | $1.5M | $944.0K | $1.3M | $1.9M | $757.0K | $152.0K | — | — |
| Total current liabilities | $20.4M | $24.8M | $20.5M | $15.4M | $15.2M | $9.0M | $5.4M | — | — |
| Long-term debt | — | — | — | — | $10.5M | — | — | — | — |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M | $9.2M | $6.1M | — | — |
| Retained earnings | -$692.2M | -$562.8M | -$434.9M | -$334.2M | -$245.1M | -$166.4M | -$92.7M | — | — |
| Total equity | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M | $289.8M | -$90.1M | -$64.4M | -$43.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$111.0M | -$112.7M | -$85.7M | -$75.1M | -$59.5M | -$45.3M | -$23.5M | -$20.7M | — |
| Depreciation and amortisation | $1.2M | $1.1M | $1.0M | $966.0K | $897.0K | $970.0K | $1.0M | $903.0K | — |
| Stock-based compensation | $25.0M | $20.2M | $15.2M | $14.5M | $12.9M | $5.3M | $1.1M | $469.0K | — |
| Capital expenditure | $712.0K | $1.2M | $849.0K | $2.1M | $939.0K | $667.0K | $768.0K | $525.0K | — |
| Investing cash flow | -$148.0M | $22.1M | -$43.4M | -$109.2M | $158.4M | -$216.0M | -$768.0K | -$508.0K | — |
| Financing cash flow | $245.3M | $126.5M | $85.7M | $25.2M | $49.1M | $250.5M | $70.8M | $38.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-186911.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$21.4M | -$26.9M | -$73.7M | -$78.7M | -$89.1M | -$100.7M | -$127.8M | -$129.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |